Bronstein, Gewirtz & Grossman, LLC Investigates Potential Claims against Corcept Therapeutics Incorporated
New York, NY – March 3, 2025
Bronstein, Gewirtz & Grossman, LLC, a prominent securities law firm, is currently investigating potential claims on behalf of purchasers of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQ: CORT). The investigation focuses on whether Corcept and certain of its officers or directors have violated the federal securities laws.
Background on Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a biopharmaceutical company engaged in the discovery, development, and commercialization of drugs for the treatment of various endocrine disorders. Its lead product is Korlym, a cortisol synthesis inhibitor indicated for the treatment of Cushing’s syndrome in patients with iCushing’s syndrome who have type 2 diabetes mellitus and are not adequately controlled on maximally tolerated doses of one or two drugs commonly used to treat hypertension and diabetes.
Investigation Details
The investigation concerns whether Corcept and certain of its officers or directors have made false and/or misleading statements and/or failed to disclose material information to the investing public. Specifically, the investigation focuses on certain statements made by the Company regarding its financial condition, business prospects, and the commercial potential of Korlym.
Effects on Individual Investors
If you purchased Corcept securities, the investigation may impact you. You may be entitled to compensation for your losses if the investigation uncovers evidence of securities law violations. It is crucial to consult with a securities attorney as soon as possible to discuss your legal rights and potential remedies. You can assist the investigation by providing information about any shares you own, the price you paid, and when you purchased them. Visit bgandg.com/CORT for more information.
Effects on the World
The potential consequences of this investigation extend beyond individual investors. If it is determined that Corcept and its officers or directors have engaged in securities fraud, the Company’s reputation may suffer, potentially impacting its business relationships, investor confidence, and stock price. Moreover, such findings may lead to regulatory action against the Company, resulting in fines, penalties, and other consequences. The truthful disclosure of material information is essential for maintaining the integrity of the securities markets and protecting investors.
Conclusion
Bronstein, Gewirtz & Grossman, LLC is dedicated to ensuring that investors receive the compensation they are entitled to if securities laws have been violated. If you purchased Corcept securities and believe that you have suffered losses as a result of misrepresentations or omissions, we encourage you to contact us for a free consultation. Your cooperation in providing information about your holdings can help further the investigation and potentially lead to recovery for all affected investors. For more information, please visit bgandg.com/CORT.
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Corcept Therapeutics Incorporated
- Investigation focuses on potential securities law violations
- Individual investors may be entitled to compensation for losses
- Visit bgandg.com/CORT for more information
- Company’s reputation and business relationships may be impacted
- Regulatory action against the Company possible
